BioOutsource Global Expansion
BioOutsource Ltd has announced that the last 12 months have been an exceptional growth year for the company. Global demand for outsourced testing services, coupled with BioOutsource’s continued investment in R&D and the opening of a state of the art BioSimilar Centre of Excellence in Glasgow in February 2014, has driven continued development of the company and created the need to establish a new North American Testing Facility in 2015.
BioOutsource revenues have grown by more than 40% over the last 12 months with positive growth delivered across all business units. The company continues to strengthen and reinforce its position as market leader in the biological analysis of biosimilar molecules.
BioOutsource CEO, Gerry MacKay commented: “This year has been an exceptional year for BioOutsource, as we continue to grow and win more market share. Our biggest growth market has without doubt been North America, where we have seen sales triple in the past year.”
Following the successful opening of a US office in 2013, based in the BioTechnology Hub of Cambridge, MA, the company plans to open a Laboratory Facility in the Massachusetts area in early 2015 to service their North American & Latin American clients. The new Laboratory Facility will support and strengthen the company’s BioSimilar and BioSafety service offering.
“North America has always been an essential strategic element of our global expansion plans, exemplified by our US office and active membership of MassBio. We are already a global company and the time is right to extend our global client footprint with the addition of a new facility in the US. The new facility will benefit our existing and new clients, improving logistics and ensuring our technical experts are close by.”
Robert K. Coughlin, President & CEO of MassBio commented: “We are excited to welcome Gerry and his team to Massachusetts, as the gateway into business in the US.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance